大B细胞淋巴瘤CD19-CAR-T治疗失败后首次治疗结局
在305例接受CD19-CAR-T的成人中,182例出现疾病复发或进展(1年累积发生率63% [95%CI: 57-69])。CAR-T失败后接受后续抗肿瘤治疗的135/182例(74%)患者中,自首次CAR-T后治疗起中位OS为8个月(95%CI 5.6-11.0)。传统化疗未见完全缓解,而polatuzumab或来那度胺方案完全缓解率超过30%。
要点
- CAR-T失败后1年累积复发/进展发生率为63%(95%CI 57-69)。
- CAR-T后首次治疗中位OS为8个月(95%CI 5.6-11.0)。
- 传统化疗无完全缓解,polatuzumab或来那度胺方案完全缓解率超过30%。
核心结论
- 在迄今最大样本的CD19-CAR-T后进展或复发患者分析中,生存期较差,但polatuzumab和来那度胺等新药可能具有前景。
研究设计与样本
- 对305例接受CD19-CAR-T的成人进行回顾性分析,其中182例出现疾病复发或进展。
主要发现
- 305例接受CD19-CAR-T的成人中,182例出现疾病复发或进展,1年累积发生率为63%(95%CI: 57-69)。
- 52例CAR-T后活检经流式细胞术评估,其中49例(94%)表达CD19。
- 135/182例(74%)CAR-T治疗失败患者接受了后续抗肿瘤治疗。
- 自首次CAR-T后治疗起中位OS为8个月(95%CI 5.6-11.0)。
- CAR-T后治疗患者中,与较差OS相关的因素包括:CAR-T前大肿块病变(HR 2.27 [1.10-4.72])、对CAR-T无反应(HR 2.33 [1.02-5.29])、年龄>65岁(HR 2.65 [1.49-4.73])及CAR-T后治疗时LDH升高(HR 2.95 [1.61-5.38])。
关键数值与推荐
- 存在≥2个上述因素者OS劣于≤1个者(56% vs. 19%)。
- 传统化疗未观察到完全缓解,而polatuzumab或来那度胺方案完全缓解率超过30%。
临床怎么用
- CAR-T失败后,polatuzumab、标准化疗和来那度胺方案是最常见的治疗选择。
- 传统化疗未观察到完全缓解,而polatuzumab或来那度胺方案完全缓解率超过30%,作者认为这些新药可能具有前景。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Persistence or recurrence of large B-cell lymphoma after CD19-CAR-T is common, yet data guiding management are limited. We describe outcomes and features following CAR-T treatment failure. Of 305 adults who received CD19-CAR-T, 182 experienced disease recurrence or progression (1-year cumulative incidence 63% [95%CI: 57-69]). Of 52 post-CAR-T biopsies evaluated by flow cytometry, 49 (94%) expressed CD19. Subsequent anti-cancer treatment was administered in 135/182 (74%) patients with CAR-T treatment failure. Median OS from the first post-CAR-T treatment was 8 months (95%CI 5.6-11.0). Polatuzumab-, standard chemotherapy-, and lenalidomide-based treatments were the most common approaches after CAR-T. No complete responses (CRs) were observed with conventional chemotherapy, while CR rates exceeding 30% were seen following polatuzumab- or lenalidomide-based therapies. Factors associated with poor OS among patients treated post-CAR-T were pre-CAR-T bulky disease (HR 2.27 [1.10-4.72]), lack of response to CAR-T (2.33 [1.02-5.29]), age >65 years (HR 2.65 [1.49-4.73]) and elevated LDH at post-CAR-T treatment (HR 2.95 [1.61-5.38]). The presence of ≥2 of these factors was associated with inferior OS compared to ≤1 (56% vs. 19%). In this largest analysis to date of patients who progressed or relapsed after CD19-CAR-T, survival is poor, though novel agents such as polatuzumab and lenalidomide may have hold promise.
引用
- Alarcon Tomas A, Fein JA, Fried S, et al. Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma. Leukemia. 2022. PMID: 36335261. doi:10.1038/s41375-022-01739-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。